These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 6193364

  • 1. Angiotensin-converting enzyme inhibitory activity of SCH 31846, a new non-sulfhydryl inhibitor.
    Sybertz EJ, Baum T, Ahn HS, Nelson S, Eynon E, Desiderio DM, Pula K, Becker F, Sabin C, Moran R, Vander Vliet G, Kastner B, Smith E.
    J Cardiovasc Pharmacol; 1983; 5(4):643-54. PubMed ID: 6193364
    [Abstract] [Full Text] [Related]

  • 2. Effect of N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo.
    Gross DM, Sweet CS, Ulm EH, Backlund EP, Morris AA, Weitz D, Bohn DL, Wenger HC, Vassil TC, Stone CA.
    J Pharmacol Exp Ther; 1981 Mar; 216(3):552-7. PubMed ID: 6259322
    [Abstract] [Full Text] [Related]

  • 3. Angiotensin converting enzyme inhibitory activity of SCH 33844 (spirapril) in rats, dogs and monkeys.
    Sybertz EJ, Baum T, Ahn HS, Desiderio DM, Pula KK, Tedesco R, Washington P, Sabin C, Smith E, Becker F.
    Arch Int Pharmacodyn Ther; 1987 Apr; 286(2):216-29. PubMed ID: 3036028
    [Abstract] [Full Text] [Related]

  • 4. Attenuation of pressor responses to intracerebroventricular angiotensin I by angiotensin converting enzyme inhibitors and their effects on systemic blood pressure in conscious rats.
    Baum T, Becker FT, Sybertz EJ.
    Life Sci; 1983 Mar 21; 32(12):1297-303. PubMed ID: 6300578
    [Abstract] [Full Text] [Related]

  • 5. Pharmacological properties of the new orally active angiotensin converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl] -(1S,3S,5S)-2-azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498).
    Becker RH, Schölkens BA, Metzger M, Schulze KJ.
    Arzneimittelforschung; 1984 Mar 21; 34(10B):1411-6. PubMed ID: 6097267
    [Abstract] [Full Text] [Related]

  • 6. Pharmacological properties of the converting enzyme inhibitor, enalapril maleate (MK-421).
    Sweet CS.
    Fed Proc; 1983 Feb 21; 42(2):167-70. PubMed ID: 6295819
    [Abstract] [Full Text] [Related]

  • 7. Relationship between angiotensin I blockade and antihypertensive properties of single doses of MK-421 and captopril in spontaneous and renal hypertensive rats.
    Sweet CS, Arbegast PT, Gaul SL, Blaine EH, Gross DM.
    Eur J Pharmacol; 1981 Dec 03; 76(2-3):167-76. PubMed ID: 6174351
    [Abstract] [Full Text] [Related]

  • 8. CI-906 and CI-907: new orally active nonsulfhydryl angiotensin-converting enzyme inhibitors.
    Kaplan HR, Cohen DM, Essenburg AD, Major TC, Mertz TE, Ryan MJ.
    Fed Proc; 1984 Apr 03; 43(5):1326-9. PubMed ID: 6323223
    [Abstract] [Full Text] [Related]

  • 9. Angiotensin-converting enzyme inhibition, anti-hypertensive activity and hemodynamic profile of trandolapril (RU 44570).
    Brown NL, Badel MY, Benzoni F, Zanirato J, Vincent JC, Fichelle J, Worcel M.
    Eur J Pharmacol; 1988 Mar 22; 148(1):79-91. PubMed ID: 3383998
    [Abstract] [Full Text] [Related]

  • 10. Pharmacologic, metabolic, and toxicologic profile of spirapril (SCH 33844), a new angiotensin converting inhibitor.
    Sybertz EJ, Watkins RW, Ahn HS, Baum T, La Rocca P, Patrick J, Leitz F.
    J Cardiovasc Pharmacol; 1987 Mar 22; 10 Suppl 7():S105-8. PubMed ID: 2485040
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of angiotensin I-converting enzyme with S 9490: biochemical effects, interspecies differences, and role of sodium diet in hemodynamic effects.
    Laubie M, Schiavi P, Vincent M, Schmitt H.
    J Cardiovasc Pharmacol; 1984 Mar 22; 6(6):1076-82. PubMed ID: 6084763
    [Abstract] [Full Text] [Related]

  • 12. Systemic effects resulting from topical ocular administration of SCH 33861, a novel ACE inhibitor ocular hypotensive agent.
    Watkins RW, Baum T, Tedesco RP, Pula K, Barnett A.
    J Ocul Pharmacol; 1988 Mar 22; 4(2):93-100. PubMed ID: 3049862
    [Abstract] [Full Text] [Related]

  • 13. Fosinopril, a phosphinic acid inhibitor of angiotensin I converting enzyme: in vitro and preclinical in vivo pharmacology.
    DeForrest JM, Waldron TL, Harvey C, Scalese B, Rubin B, Powell JR, Petrillo EW, Cushman DW.
    J Cardiovasc Pharmacol; 1989 Nov 22; 14(5):730-6. PubMed ID: 2481187
    [Abstract] [Full Text] [Related]

  • 14. Decreased vascular responsiveness produced by angiotensin-converting enzyme inhibitors in the rat isolated kidney.
    Chiba S, Quilley CP, McGiff JC.
    Hypertension; 1982 Nov 22; 4(3 Pt 2):80-5. PubMed ID: 6175573
    [Abstract] [Full Text] [Related]

  • 15. Comparison of the actions of the angiotensin-converting enzyme inhibitors enalapril and S-9490-3 in sodium-deplete and sodium-replete spontaneously hypertensive rats.
    DiNicolantonio R, Doyle AE.
    J Cardiovasc Pharmacol; 1985 Nov 22; 7(5):937-42. PubMed ID: 2413304
    [Abstract] [Full Text] [Related]

  • 16. Comparative effects of enalapril, enalaprilic acid and captopril in blocking angiotensin I-induced pressor and dipsogenic responses in spontaneously hypertensive rats.
    Gaul SL, Martin GE, Sweet CS.
    Clin Exp Hypertens A; 1984 Nov 22; 6(6):1187-206. PubMed ID: 6086183
    [Abstract] [Full Text] [Related]

  • 17. Antihypertensive effects of CI-907 (indolapril): a novel nonsulfhydryl angiotensin converting enzyme inhibitor.
    Ryan MJ, Boucher DM, Cohen DM, Essenburg AD, Major TC, Mertz TE, Olszewski BJ, Randolph AE, Singer RM, Kaplan HR.
    J Pharmacol Exp Ther; 1984 Feb 22; 228(2):312-8. PubMed ID: 6319675
    [Abstract] [Full Text] [Related]

  • 18. [Angiotensin converting enzyme inhibitory activity of MK-0521 in vivo and antihypertensive effect of its single oral administration on blood pressure and effect on the renin-angiotensin system in 2-kidney Goldblatt hypertensive dogs].
    Oda M, Ino Y, Suzuki K, Sato T, Iwamoto S, Iwaki M.
    Nihon Yakurigaku Zasshi; 1989 Apr 22; 93(4):225-34. PubMed ID: 2545579
    [Abstract] [Full Text] [Related]

  • 19. Pharmacological properties of FPL 63547, a novel inhibitor of angiotensin-converting enzyme.
    Carr RD, Higgs L, Killingback PG, Nicol AK, O'Connor SE, Robson A, Wells E, Simpson WT.
    Br J Pharmacol; 1990 May 22; 100(1):83-9. PubMed ID: 2164863
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of angiotensin converting enzyme by 2-[N-[(S)-1-carboxy-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2-azabicyclo [3.3.0]octane-3-carboxylic acid (Hoe 498 diacid). Comparison with captopril and enalaprilat.
    Bünning P.
    Arzneimittelforschung; 1984 May 22; 34(10B):1406-10. PubMed ID: 6097266
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.